Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Immatics in a ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Shattuck Labs (NasdaqGS:STTK) with a Outperform ...

Leerink Partnrs lowered shares of Equillium (NASDAQ:EQ – Free Report) from a strong-buy rating to a hold rating in a research report released on Friday,Zacks.com reports. Leerink Partnrs also issued ...

In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (BMV:MEDP) with a Market Perform recommendation. Invesco holds 1,085K shares representing 3.56% ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.